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substantial reductions in doctor demand and substantial soci-
etal cost savings. Since prior research suggests no adverse
impact on adherence to drugs and follow-up of these innova-
tions, serious consideration should be given to policy changes
to adopt substituting for doctor for routine HIV follow-up
care.
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OBJECTIVE: To evaluate all-cause mortality and cost of treat-
ment in patients with refractory invasive aspergillosis (rIA)
treated with either posaconazole or other systemic anti-fungal
(SAF) therapies. METHODS: All-cause mortality and cost of
salvage therapy of posaconazole oral suspension (800 mg/day)
and other SAF treatments were assessed using a multicenter
clinical study in patients with IA refractory to or intolerant of
conventional antifungal therapy. Data from external controls
were collected retrospectively providing a comparative refer-
ence group. All patients had failed to improve or progress with
prior SAF therapies. Prior SAF treatments for the majority of
patients were liposomal amphotericin B, amphotericin B, or
itraconazole. Cases of aspergillosis deemed evaluable by a
blinded data review committee included 107 posaconazole and
86 control subjects (modiﬁed intent-to-treat population). The
populations were comparable regarding pre-speciﬁed demo-
graphic and clinical characteristics. All-cause mortality were
analyzed using the survival technique. Economic evaluations
were conducted using survival data and costs of pharmaco-
therapy one year post therapy (2007 Canadian dollars).
RESULTS: Signiﬁcantly more posaconazole-treated patients
responded to therapy as compared with other SAF therapies.
Patients with rIA treated with posaconazole appeared to confer
a highly signiﬁcant survival beneﬁt over the control cases. The
cumulative rates of survival at 30 days and at the end of
therapy were 74% and 38%, respectively. For controls, those
survival rates were 49% and 22%, respectively. The Kaplan-
Meier survival curves were signiﬁcantly different (P = 0.0003).
In addition, posaconazole appeared to be a cost-saving option
for the treatment of rIA compared with the active comparator
receiving standard SAF treatments ($14,839 vs. $38,158). Sen-
sitivity analyses demonstrated the robustness of the results
over a range of alternative values for costs and outcomes.
CONCLUSION: Treatment with posaconazole compared with
other SAF treatments provided a signiﬁcant survival beneﬁt in
patients with rIA at lower cost of drug therapy.
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OBJECTIVE: The “AIDS epidemic update” (2007) published
by the United Nations (UN) and World Health Organization
(WHO), reports lower estimates of incidences of persons
infected with HIV globally. This study evaluates the cost
savings of these lower estimates on costs associated with
patients being treated by antiretroviral (ARV) drugs and oppor-
tunistic infection (OI) prophylaxis. METHODS: Estimated dif-
ferences in incidences of persons infected with HIV for the
eight global regions in years 2006 and 2007 were calculated
from UN reports. This difference was then multiplied by the
average percentage of patients on ARV and OI treatment.
Further, to derive the total cost savings associated with the
ARV cohort, the number of patients on ARV medication was
multiplied by a weighted average of ﬁrst and second line ARV
drug costs, lab costs, counseling costs, inpatient costs and out-
patient costs, for each region. Conversely, only counseling and
OI drug costs were included in the total cost of patients receiv-
ing OI prophylaxis treatment, for each region. Costs were
reported in 2006 US dollars. Sensitivity analysis performed on
all key parameters. RESULTS: The reduction of incidences of
persons infected with HIV from 2006 to 2007 resulted in a
total cost savings of $309.5 million, or 42%. Separately, the
patients being treated by ARV drugs attributed a cost savings of
$274.7 million, contrary to patients on OI drugs attributing
$34.8 million to cost savings. The greatest savings were shown
in the Sub-Saharan Africa region ($191.1 million). CONCLU-
SION: Based on the revised estimates, the worldwide savings is
a large percentage of the treatment budget. Notwithstanding
increased incidence rates in subsequent years, these savings
should continue beyond 2007.
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OBJECTIVE: Restricted information exists to guide clinicians in
selecting antibiotics for diabetic foot infections in Colombia.
Because this serious complication causes substantial morbidity,
mortality, and incurs major health care costs, we developed a
decision tree model to determine, from the Ministry of Health’s
perspective, the cost-effectiveness in Colombia of the treatments
recommended by the Infectious Diseases Society of America
guidelines for mild diabetic foot infections. METHODS: A
decision-tree model was developed using TreeAge® Pro-2007
and clinical experts. Success probabilities were derived from
published randomized controlled trials. Drug costs were
obtained from the Farmaprecios Guía de precios sugeridos al
público, promedio del mercado para farmacias independientes.
No 98 September–Octuber 2007. Thomson PLM. S.A. Bogotá
D.C. and amputation and hospitalization costs from ISS 2001/
2004 database, with values adjusted to 2007 using the Colom-
bian inﬂation. One-way and two-way sensitivity analyses were
performed to test the robustness of the decision tree model by
varying the clinical success rates and costs of antibiotics. Proba-
bilistic sensitivity analyses were also performed using Monte
Carlo simulations. RESULTS: Clindamycin was cost-effective,
dominating all other choices, and cephalexin had the next best
proﬁle. Expected success rates were 99.4% for clindamycin,
97.8% for cephalexin, 95.4% for amoxicillin-clavulanate,
95.2% for oxacillin and 95.0% for levoﬂoxacin. The expected
cost of clindamycin ($315,200 pesos (USD$157.28)) was lower
than the next best alternative, cephalexin $366,560 pesos
(USD$182.14); a cost difference of $51,360 pesos (USD$24.86)
per patient treated. However, success rates were based on a single
small trial for each drug (n < 30 for each). In sensitivity analyses,
the model/decision was sensitive to changes in efﬁcacy rates and
costs within plausible ranges for clindamycin and cephalexin.
CONCLUSION: Clindamycin was cost-effective in treating mild
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